United States Therapeutic Plasma Exchange Market, 2020-2025 - Increasing Installation of Devices in Hospitals for Therapeutic Plasma Exchange to Drive Market Growth - PRNewswire

sutitong.blogspot.com

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- The "US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users, Covid-19 Impact - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The US therapeutic plasma exchange market is projected to reach USD 243.3 million by 2025 from USD 178.9 million in 2020, at a CAGR of 6.3% during the forecast period.

The report analyzes the market for various US therapeutic plasma exchange and their adoption pattern. It aims at estimating the market size and future growth potential of the US therapeutic plasma exchange market and different segments such as products, end-user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Rising Prevalence of Chronic Diseases
4.2.1.2 Technological Advancements
4.2.2 Restraints
4.2.2.1 High Cost of Apheresis Devices and Therapeutic Plasma Exchange Procedures and Installation of Apheresis Devices Through a Rental Model
4.2.3 Opportunities
4.2.3.1 Therapeutic Plasma Exchange for Pediatric Patients
4.2.4 Challenges
4.2.4.1 Dearth of Skilled Professionals

5 Industry Insights
5.1 Industry Trends
5.1.1 Impact of COVID-19 on the Therapeutic Plasma Exchange Market
5.1.2 New Indications for Plasma Products
5.2 Porter's Five Forces Analysis
5.3 Value Chain Analysis
5.4 Regulatory Analysis
5.4.1 US

6 US Therapeutic Plasma Exchange Market, by Product & Technology
6.1 US Therapeutic Plasma Exchange Market, by Product
6.1.1 Introduction
6.1.2 Consumables
6.1.2.1 Recurrent Use of Consumables to Drive the Growth of this Segment
6.1.3 Devices
6.1.3.1 Increasing Installation of Devices in Hospitals for Therapeutic Plasma Exchange to Drive Market Growth
6.2 US Therapeutic Plasma Exchange Market, by Technology
6.2.1 Introduction
6.2.2 Centrifugation
6.2.2.1 Centrifugation Technology to Dominate the US Therapeutic Plasma Exchange Market
6.2.3 Membrane Separation
6.2.3.1 Recent Advances in Developing Highly Permeable Filters are Supporting the Growth of this Market

7 US Therapeutic Plasma Exchange Market, by Indication
7.1 Introduction
7.2 Neurological Disorders
7.2.1 Neurological Disorders Accounted for the Largest Market Share in 2019
7.2.1.1 Guillain-Barre Syndrome
7.2.1.2 Chronic Inflammatory Demyelinating Polyneuropathy
7.2.1.3 Myasthenia Gravis
7.2.1.4 Multiple Sclerosis
7.2.1.5 Pandas
7.3 Hematologic Disorders
7.3.1 Increasing Prevalence and Incidence of Hematologic Disorders Will Boost the Demand for Therapeutic Plasma Exchange
7.3.1.1 Thrombotic Thrombocytopenic Purpura
7.3.1.2 Atypical Hemolytic Uremic Syndrome
7.3.1.3 Hyperviscosity Syndrome
7.3.1.4 Severe/Symptomatic Cryoglobulinemia
7.4 Renal Disorders
7.4.1 Therapeutic Plasma Exchange is Regarded as One of the Most Useful Treatment Options for Several Renal Disorders
7.4.1.1 Goodpasture Syndrome
7.4.1.2 Wegener's Granulomatosis (Anca)-Associated Rapidly Progressive Glomerulonephritis
7.4.1.3 Antibody-Mediated Renal Transplant Rejection
7.5 Metabolic Disorders
7.5.1 Increasing Adoption of Plasma Exchange for Diabetes and Other Metabolic Disorders to Drive Market Growth
7.5.1.1 Familial Hypercholesterolemia (Homozygous)
7.6 Other Indications

8 US Therapeutic Plasma Exchange Market, by End-User
8.1 Introduction
8.2 Blood Collection Centers & Blood Component Providers
8.2.1 Blood Collection Centers & Blood Component Providers are the Largest End-users of Therapeutic Plasma Exchange
8.3 Hospitals & Transfusion Centers
8.3.1 Hospitals & Transfusion Centers Segment to Register the Highest CAGR During the Forecast Period
8.4 Other End-users

9 Competitive Landscape
9.1 Overview
9.2 Market Evaluation Framework
9.3 Competitive Situations and Trends
9.3.1 Product Launches & Approvals
9.3.2 Expansions
9.3.3 Acquisitions
9.3.4 Collaborations

10 Company Evaluation Matrix and Company Profiles
10.1 Company Evaluation Matrix Definition & Methodology
10.2 Competitive Leadership Mapping
10.2.1 Stars
10.2.2 Emerging Leaders
10.2.3 Pervasive
10.2.4 Emerging Companies
10.3 Market Share Analysis
10.4 Company Profiles
10.4.1 Terumo Bct, Inc.
10.4.2 Fresenius Se & Co. KGaA
10.4.3 Haemonetics Corporation
10.4.4 Baxter International Inc.
10.4.5 Asahi Kasei Medical Co. Ltd.
10.4.6 B. Braun Melsungen Ag
10.4.7 Cerus Corporation
10.4.8 Kaneka Corporation
10.4.9 Kawasumi Laboratories, Inc.
10.4.10 Nikkiso Co., Ltd.
10.4.11 Miltenyi Biotec
10.4.12 Medica S.P.A.
10.4.13 Medicap Clinic GmbH
10.4.14 Infomed